Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Arcutis Biotherapeutics (ARQT) Accumulated Depreciation & Amortization (2020 - 2025)

Arcutis Biotherapeutics has reported Accumulated Depreciation & Amortization over the past 6 years, most recently at $3.2 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $3.2 million for Q4 2025, up 26.68% from a year ago — trailing twelve months through Dec 2025 was $3.2 million (up 26.68% YoY), and the annual figure for FY2025 was $3.2 million, up 26.68%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $3.2 million at Arcutis Biotherapeutics, up from $2.6 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for ARQT hit a ceiling of $3.2 million in Q4 2025 and a floor of $176000.0 in Q1 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $1.1 million (2022), compared with a mean of $1.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 582.05% in 2021 and later rose 26.68% in 2025.
  • Arcutis Biotherapeutics' Accumulated Depreciation & Amortization stood at $532000.0 in 2021, then soared by 116.73% to $1.2 million in 2022, then soared by 66.87% to $1.9 million in 2023, then surged by 33.26% to $2.6 million in 2024, then rose by 26.68% to $3.2 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $3.2 million (Q4 2025), $2.6 million (Q4 2024), and $1.9 million (Q4 2023) per Business Quant data.